Researchers at the Massachusetts Institute of Technology have built a small automated microfluidics device that can help diagnose sepsis in about 25 minutes using less than a finger-prick of blood. The advance targets a major gap in emergency care: sepsis can worsen fast, but common lab tests for key blood markers are often too slow, too bulky, or require too much blood to guide quick decisions. MIT’s system focuses on interleukin-6, or IL-6, a protein involved in the body’s inflammatory response that can rise during sepsis. By shrinking a standard magnetic-bead laboratory assay onto a chip-sized platform, the team created a test that uses only about five microliters of blood. That is a tiny volume compared with conventional assays that may need around a milliliter and take hours to return a result. The researchers say the device can detect IL-6 at concentrations as low as 16 picograms per milliliter, below the level considered clinically significant for sepsis. For a condition where timing matters, the goal is simple: give clinicians a fast, repeatable readout they can use close to the patient rather than waiting on a central lab.
A fast test for a fast-moving condition
Sepsis is an extreme immune response to infection. Instead of containing the threat, the body’s inflammatory machinery can spiral into widespread damage, raising the risk of septic shock and organ failure.
That makes speed critical. A patient’s condition can change quickly, so a test that arrives hours later may be much less useful than one that gives an answer while treatment decisions are still being made.
Why IL-6 matters
The MIT device is designed to measure IL-6, a signaling protein that helps cells communicate during inflammation. You can think of IL-6 like an alarm message sent through the bloodstream: when infection or injury triggers the immune system, the message volume can surge.
In sepsis, that signal can become clinically important, but IL-6 is not always present in large amounts. The MIT team noted that standard assay devices struggle to quickly detect blood levels of this protein, especially when clinicians need speed and sensitivity at the same time.
How the device works
The core idea is to miniaturize a familiar lab method. Researchers took parts of a magnetic-bead-based assay—a test that uses tiny beads to grab specific molecules—and integrated them into an automated microfluidic system.
Microfluidics is the science of moving very small amounts of liquid through tiny channels, almost like plumbing on a chip. In this case, the beads are coated with an antibody, a molecule that acts like a highly selective hook, designed to bind IL-6 from a small blood sample.
Once the sample enters the device, the automated system handles the steps that would normally require larger equipment and more manual processing. That matters because automation can reduce variability and make the test easier to run in settings outside a full clinical laboratory.
Small sample, high sensitivity
One of the most practical features is the sample size. The device uses roughly five microliters of blood, which is less than a typical finger prick and far smaller than the volumes needed for many conventional assays.
The team reports that the system can detect IL-6 concentrations down to 16 picograms per milliliter. That level is important because it falls below concentrations associated with sepsis, meaning the device is sensitive enough to pick up clinically relevant changes rather than only obvious, late-stage signals.
How it compares with existing options
According to the researchers, conventional protein biomarker tests are often bulky, expensive, and slow. They can require about a milliliter of blood and may take hours to provide results, which limits their usefulness in urgent care.
Portable point-of-care systems already exist, but the MIT team says those tools can still be costly and may capture only a small amount of protein. Their device aims to combine the convenience of point-of-care testing with improved sensitivity for a biomarker that is not abundant in blood.
What the researchers said
Dan Wu, a PhD student in MIT’s Department of Mechanical Engineering, framed the device as a tool for a disease that does not wait. “For an acute disease, such as sepsis, which progresses very rapidly and can be life-threatening, it’s helpful to have a system that rapidly measures these non-abundant biomarkers,” Wu said.
He also pointed to another advantage: repeat testing. Because the device needs so little blood and produces results quickly, it could allow clinicians to monitor how the disease changes over time instead of relying on a single snapshot.
Why This Matters
The most promising part of this work is not just miniaturization for its own sake. It is the possibility of moving a sensitive sepsis-related blood test closer to the bedside, where clinicians need fast information to judge whether a patient is getting better or worse.
That could be especially useful in emergency departments, intensive care units, and other settings where repeated blood draws are common and time is tightly linked to outcomes. A five-microliter test that runs in about 25 minutes could make frequent monitoring much more practical, particularly for fragile patients.
The MIT device is still best understood as a technical step toward better point-of-care diagnostics rather than a complete replacement for all sepsis testing. But it shows how shrinking a proven laboratory assay onto a microfluidic platform can preserve sensitivity while cutting time, blood volume, and equipment demands. If future validation confirms the device’s performance in real clinical settings, systems like this could help doctors spot sepsis earlier and track it more closely as treatment unfolds.